Do analysts recommend JYNT or SBC?

SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 111.44%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 SBC Medical Group 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, JYNT or SBC?

SBC Medical Group has higher revenue and earnings than Joint. SBC Medical Group is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.26 SBC Medical Group $173.61M 2.38 $50.99M $0.47 8.55

Is JYNT or SBC more profitable?

SBC Medical Group has a net margin of 27.99% compared to Joint's net margin of 6.49%. SBC Medical Group's return on equity of 18.47% beat Joint's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% SBC Medical Group 27.99% 18.47% 13.10%

Does the media refer more to JYNT or SBC?

In the previous week, Joint and Joint both had 2 articles in the media. Joint's average media sentiment score of 0.93 beat SBC Medical Group's score of 0.93 indicating that Joint is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SBC Medical Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate JYNT or CCRN?

Cross Country Healthcare has a consensus price target of $12.05, indicating a potential downside of 9.06%. Given Cross Country Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Cross Country Healthcare is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cross Country Healthcare 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90

Do analysts rate JYNT or VMD?

Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 58.37%. Given Viemed Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Viemed Healthcare is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Viemed Healthcare 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has preferable earnings and valuation, JYNT or VMD?

Viemed Healthcare has higher revenue and earnings than Joint. Viemed Healthcare is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.26 Viemed Healthcare $270.28M 1.25 $14.93M $0.36 24.56

Does the media favor JYNT or VMD?

In the previous week, Viemed Healthcare had 7 more articles in the media than Joint. MarketBeat recorded 9 mentions for Viemed Healthcare and 2 mentions for Joint. Viemed Healthcare's average media sentiment score of 1.32 beat Joint's score of 0.93 indicating that Viemed Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viemed Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate JYNT or TACO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, JYNT or TACO?

Joint has higher revenue and earnings than Berto Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.17 $2.91M $0.27 31.26 Berto Acquisition N/A N/A N/A N/A N/A

Does the media prefer JYNT or TACO?

In the previous week, Berto Acquisition had 2 more articles in the media than Joint. MarketBeat recorded 4 mentions for Berto Acquisition and 2 mentions for Joint. Joint's average media sentiment score of 0.93 beat Berto Acquisition's score of 0.71 indicating that Joint is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Joint 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Berto Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BDSX or JYNT?

Biodesix currently has a consensus price target of $31.33, suggesting a potential upside of 18.96%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings & valuation, BDSX or JYNT?

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.14 -$35.26M -$3.17 N/A Joint $54.90M 2.17 $2.91M $0.27 31.26

Is BDSX or JYNT more profitable?

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Joint 6.49% 12.02% 3.47%

Joint (JYNT) Competitors

$8.44 +0.01 (+0.12%)

As of 08/31/2026 04:00 PM Eastern

Compare

JYNT vs. SBC, CCRN, VMD, TACO, and BDSX

Should you buy Joint stock or one of its competitors? Joint's main competitors and comparable companies include SBC Medical Group (SBC), Cross Country Healthcare (CCRN), Viemed Healthcare (VMD), Berto Acquisition (TACO), and Biodesix (BDSX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Joint compare to SBC Medical Group?

Joint (NASDAQ:JYNT) and SBC Medical Group (NASDAQ:SBC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

76.9% of Joint shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 81.7% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SBC Medical Group has a net margin of 27.99% compared to Joint's net margin of 6.49%. SBC Medical Group's return on equity of 18.47% beat Joint's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
SBC Medical Group	27.99%	18.47%	13.10%

SBC Medical Group has higher revenue and earnings than Joint. SBC Medical Group is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
SBC Medical Group	$173.61M	2.38	$50.99M	$0.47	8.55

In the previous week, Joint and Joint both had 2 articles in the media. Joint's average media sentiment score of 0.93 beat SBC Medical Group's score of 0.93 indicating that Joint is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SBC Medical Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Joint has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

SBC Medical Group has a consensus price target of $8.50, suggesting a potential upside of 111.44%. Given SBC Medical Group's stronger consensus rating and higher probable upside, analysts plainly believe SBC Medical Group is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

SBC Medical Group beats Joint on 11 of the 15 factors compared between the two stocks.

How does Joint compare to Cross Country Healthcare?

Joint (NASDAQ:JYNT) and Cross Country Healthcare (NASDAQ:CCRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Cross Country Healthcare has a consensus price target of $12.05, indicating a potential downside of 9.06%. Given Cross Country Healthcare's stronger consensus rating and higher possible upside, analysts clearly believe Cross Country Healthcare is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cross Country Healthcare	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90

Joint has higher earnings, but lower revenue than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
Cross Country Healthcare	$1.00B	0.43	-$94.85M	-$3.05	N/A

Joint has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Cross Country Healthcare has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

76.9% of Joint shares are owned by institutional investors. Comparatively, 96.0% of Cross Country Healthcare shares are owned by institutional investors. 30.2% of Joint shares are owned by insiders. Comparatively, 6.3% of Cross Country Healthcare shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Joint has a net margin of 6.49% compared to Cross Country Healthcare's net margin of -9.84%. Joint's return on equity of 12.02% beat Cross Country Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Cross Country Healthcare	-9.84%	-0.74%	-0.54%

In the previous week, Joint had 2 more articles in the media than Cross Country Healthcare. MarketBeat recorded 2 mentions for Joint and 0 mentions for Cross Country Healthcare. Joint's average media sentiment score of 0.93 beat Cross Country Healthcare's score of 0.00 indicating that Joint is being referred to more favorably in the media.

Company	Overall Sentiment
Joint	Positive
Cross Country Healthcare	Neutral

Summary

Joint beats Cross Country Healthcare on 11 of the 15 factors compared between the two stocks.

How does Joint compare to Viemed Healthcare?

Joint (NASDAQ:JYNT) and Viemed Healthcare (NASDAQ:VMD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Joint has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Viemed Healthcare has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

76.9% of Joint shares are owned by institutional investors. Comparatively, 74.2% of Viemed Healthcare shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 20.6% of Viemed Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viemed Healthcare has a consensus price target of $14.00, indicating a potential upside of 58.37%. Given Viemed Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Viemed Healthcare is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Viemed Healthcare had 7 more articles in the media than Joint. MarketBeat recorded 9 mentions for Viemed Healthcare and 2 mentions for Joint. Viemed Healthcare's average media sentiment score of 1.32 beat Joint's score of 0.93 indicating that Viemed Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viemed Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Joint has a net margin of 6.49% compared to Viemed Healthcare's net margin of 4.81%. Joint's return on equity of 12.02% beat Viemed Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Viemed Healthcare	4.81%	10.16%	7.22%

Viemed Healthcare has higher revenue and earnings than Joint. Viemed Healthcare is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
Viemed Healthcare	$270.28M	1.25	$14.93M	$0.36	24.56

Summary

Viemed Healthcare beats Joint on 9 of the 15 factors compared between the two stocks.

How does Joint compare to Berto Acquisition?

Joint (NASDAQ:JYNT) and Berto Acquisition (NASDAQ:TACO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Joint has a net margin of 6.49% compared to Berto Acquisition's net margin of 0.00%. Joint's return on equity of 12.02% beat Berto Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Berto Acquisition	N/A	N/A	N/A

76.9% of Joint shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Joint has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Berto Acquisition has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Joint has higher revenue and earnings than Berto Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.17	$2.91M	$0.27	31.26
Berto Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Berto Acquisition had 2 more articles in the media than Joint. MarketBeat recorded 4 mentions for Berto Acquisition and 2 mentions for Joint. Joint's average media sentiment score of 0.93 beat Berto Acquisition's score of 0.71 indicating that Joint is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Joint	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Berto Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Joint beats Berto Acquisition on 9 of the 10 factors compared between the two stocks.

How does Joint compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, Joint had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Joint and 1 mentions for Biodesix. Joint's average media sentiment score of 0.93 beat Biodesix's score of 0.81 indicating that Joint is being referred to more favorably in the news media.

Company	Overall Sentiment
Biodesix	Positive
Joint	Positive

Biodesix currently has a consensus price target of $31.33, suggesting a potential upside of 18.96%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts clearly believe Biodesix is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Joint has a net margin of 6.49% compared to Biodesix's net margin of -26.97%. Joint's return on equity of 12.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Joint	6.49%	12.02%	3.47%

21.0% of Biodesix shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Joint has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.14	-$35.26M	-$3.17	N/A
Joint	$54.90M	2.17	$2.91M	$0.27	31.26

Biodesix has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Joint has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Joint beats Biodesix on 11 of the 17 factors compared between the two stocks.

Get Joint News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JYNT vs. The Competition

Export

Metric	Joint	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$119.23M	$9.81B	$7.20B	$12.89B
Dividend Yield	N/A	2.56%	2.54%	11.27%
P/E Ratio	31.26	34.39	272.60	25.49
Price / Sales	2.17	4.97	627.57	97.10
Price / Cash	86.67	24.48	28.74	36.03
Price / Book	8.36	5.30	11.03	6.34
Net Income	$2.91M	$310.63M	$3.47B	$349.45M
7 Day Performance	-0.12%	-1.34%	0.14%	-0.67%
1 Month Performance	1.81%	0.36%	8.16%	4.48%
1 Year Performance	-21.42%	14.47%	24.14%	14.94%

Joint Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JYNT Joint	2.263 of 5 stars	$8.44 +0.1%	N/A	-21.4%	$119.23M	$54.90M	31.26	320	Gap Up
SBC SBC Medical Group	4.1667 of 5 stars	$4.25 +2.4%	$8.50 +100.0%	-1.5%	$437.11M	$173.61M	9.04	N/A
CCRN Cross Country Healthcare	N/A	$13.25 flat	$12.05 -9.1%	N/A	$428.05M	$1.00B	N/A	6,784
VMD Viemed Healthcare	4.6316 of 5 stars	$9.10 +0.1%	$14.00 +53.8%	+19.9%	$346.62M	$270.28M	25.28	1,382	Positive News
TACO Berto Acquisition	N/A	$10.48 +0.0%	N/A	+1.5%	$341.69M	N/A	N/A	7,892

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JYNT) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Joint (JYNT) Competitors

JYNT vs. SBC, CCRN, VMD, TACO, and BDSX

How does Joint compare to SBC Medical Group?

Summary

How does Joint compare to Cross Country Healthcare?

Summary

How does Joint compare to Viemed Healthcare?

Summary

How does Joint compare to Berto Acquisition?

Summary

How does Joint compare to Biodesix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Joint (JYNT) Competitors

JYNT vs. SBC, CCRN, VMD, TACO, and BDSX

How does Joint compare to SBC Medical Group?

Do insiders & institutionals hold more shares of JYNT or SBC?

Is JYNT or SBC more profitable?

Which has better earnings and valuation, JYNT or SBC?

Does the media refer more to JYNT or SBC?

Which has more risk and volatility, JYNT or SBC?

Do analysts recommend JYNT or SBC?

Summary

How does Joint compare to Cross Country Healthcare?

Do analysts rate JYNT or CCRN?

Which has preferable earnings and valuation, JYNT or CCRN?

Which has more risk & volatility, JYNT or CCRN?

Do insiders & institutionals have more ownership in JYNT or CCRN?

Is JYNT or CCRN more profitable?

Does the media favor JYNT or CCRN?

Summary

How does Joint compare to Viemed Healthcare?

Which has more risk and volatility, JYNT or VMD?

Do insiders and institutionals believe in JYNT or VMD?

Do analysts rate JYNT or VMD?

Does the media favor JYNT or VMD?

Is JYNT or VMD more profitable?

Which has preferable earnings and valuation, JYNT or VMD?

Summary

How does Joint compare to Berto Acquisition?

Is JYNT or TACO more profitable?

Do institutionals & insiders hold more shares of JYNT or TACO?

Which has more volatility and risk, JYNT or TACO?

Do analysts rate JYNT or TACO?

Which has better valuation & earnings, JYNT or TACO?

Does the media prefer JYNT or TACO?

Summary

How does Joint compare to Biodesix?

Does the media favor BDSX or JYNT?

Do analysts prefer BDSX or JYNT?

Is BDSX or JYNT more profitable?

Do insiders and institutionals have more ownership in BDSX or JYNT?

Which has better earnings & valuation, BDSX or JYNT?

Which has more risk & volatility, BDSX or JYNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JYNT vs. The Competition

Joint Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools